News|Articles|October 1, 2009

FDA Pipeline preview, October 2009 (doxorubicin, trabectedin, carisbamate, alogliptin/pioglitazone, HPV vaccine, pralatrexate, romidepsin, hyaluronic acid, laromustine, clofarabine, prGCD, KNS-760704, rifaximin, hexvix, quinazoline495)

Recent FDA action (through October 2009) related to doxorubicin, trabectedin, carisbamate, alogliptin/pioglitazone, HPV vaccine, pralatrexate, romidepsin, hyaluronic acid, laromustine, clofarabine, prGCD, KNS-760704, rifaximin, hexvix, and quinazoline495

Complete response

Recommended for approval

Not recommended for approval

Priority review

Orphan drug designations

Newsletter

Get the latest industry news, event updates, and more from Managed healthcare Executive.

Subscribe Now!

Related Content